Exelixis, Inc. Q2 2025 Earnings Recap

EXEL Q2 2025 July 29, 2025

Get alerts when EXEL reports next quarter

Exelixis delivered strong second-quarter performance in 2025, with cabozantinib franchise net revenues growing 19% year-over-year to $520 million, reflecting robust commercial demand.

Earnings Per Share Beat

$0.75 vs $0.65 est.

+15.4% surprise

Revenue Miss

568261000 vs 594929700 est.

-4.5% surprise

Market Reaction

1-Day -0.23%

5-Day +1.41%

30-Day +2.6%

See EXEL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Cabozantinib's U.S. net product revenues reached $520 million, driven by strong demand and a successful rollout of new indications.
Zanzalintinib is advancing as a promising oncology franchise, with pivotal trials underway and positive results from STELLAR-303 expected to support an expedited regulatory filing.
The early-stage pipeline is progressing rapidly, with several potential new therapies entering clinical evaluation, maintaining a focus on strategic capital allocation for development priorities.
Exelixis plans to continue share repurchases when stock is undervalued, while actively pursuing business development opportunities for high-potential assets.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit EXEL on AllInvestView.

Next Q3 2025